By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Afferent Pharmaceuticals 

29 Newbury Street
Suite 301
Boston  Massachusetts  02116  U.S.A.
Phone: 617-859-3099 Fax: 617-859-2891


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Afferent Pharmaceuticals Presents Updated Positive Results With AF-219 From Phase IIB Chronic Cough Study At The 2016 American Thoracic Society International Conference 5/16/2016 10:43:27 AM
Afferent Pharmaceuticals Announces Presentations Of Chronic Cough Clinical Data And Hypertension Research For The Upcoming American Thoracic Society 2016 International Conference 4/25/2016 10:45:01 AM
Afferent Pharmaceuticals Advances Novel Molecule, AF-130, To Phase I Clinical Trial 12/8/2015 8:03:24 AM
Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments Of Prabha N. Ibrahim, PhD, As Chief Technology Officer And Michelle Carpenter, JD, RAC, As Vice President, Regulatory Affairs And Project Management 11/19/2015 10:09:47 AM
Afferent Pharmaceuticals Announces Phase 2 Clinical Trial With AF-219 In Cough In Idiopathic Pulmonary Fibrosis (IPF) Patients 11/11/2015 11:34:00 AM
Afferent Pharmaceuticals Announces Positive Results In Phase 2b Chronic Cough Trial 9/28/2015 1:30:17 PM
Afferent Pharmaceuticals Raises $55 Million In Oversubscribed Crossover Financing 7/8/2015 8:22:45 AM
Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company’s Board Of Directors 12/3/2014 8:45:11 AM
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014 6:37:44 AM
Afferent Pharmaceuticals Names Kathleen Sereda Glaub As Chief Executive Officer 9/10/2014 6:27:42 AM
12
//-->